The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
KEYTRUDA Merck Sharp & Dohme (Australia) Pty Ltd
Product name
KEYTRUDA
Accepted date
Jul-2024
Active ingredients
pembrolizumab
Proposed indication
For the treatment of recurrent locally advanced or metastatic Merkel cell carcinoma.
Application type
C (new indication)
Publication date
Jul-2024